Methods of using RARγ agonists for cancer treatment
AssigneeIo Therapeutics, Inc.
InventorsMartin E. Sanders, Vidyasagar Vuligonda
Life of this patent
Estimating the term…
Abstract
The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
Claims17
A method of treating cancer comprising administering to a patient in need thereof an effective amount of an RARγ-selective agonist of the structure:
- or a pharmaceutically acceptable salt thereof, wherein R is H or C1-6 alkyl;
- R7 to R12 are independently C1-6 alkyl, a hydrogen atom, an alkoxy group, a halogen atom, a nitro group, a hydroxy group, OCF3, or COR13, wherein R13 is C1-6 alkyl or CF;
- Y is oxygen, sulfur, or NR14, wherein R14 is C1-6 alkyl;
- and the crossed double bond to the ═N—OH group indicates that stereochemistry is not specified.
A method of treating cancer, comprising infusing tumor infiltrating lymphocytes (TIL) generated or expanded, wherein the TIL are generated or expanded by contacting the TIL with an RARγ selective agonist of the structure:
- or a pharmaceutically acceptable salt thereof, wherein R is H or C1-6 alkyl;
- R7 to R12 are independently C1-6 alkyl, a hydrogen atom, an alkoxy group, a halogen atom, a nitro group, a hydroxy group, OCF3, or COR13, wherein R13 is C1-6 alkyl or CF;
- Y is oxygen, sulfur, or NR14, wherein R14 is C1-6 alkyl;
- and the crossed double bond to the ═N—OH group indicates that stereochemistry is not specified.
Dependencies are inferred from the claim text.